Tempus TO

Question 1

What does CUP stand for?

Answer 1

• Cancer of unknown primary (CUP) also known as a “tumor of unknown origin” (TUO)

Question 2

T or F, patients with CUP, typically recieve standard platinum based chemo.

Answer 2

True

Question 3

Why is this form of chemo not ideal?

Answer 3

Because it has significant negative side effects for patients and it may not even work. It’s not associated with good outcomes.

Question 4

Clinical indications for TO testing

Answer 4

True CUP/TUO- primary site of tumor origin for a metastasis is unknown, lacks clear diagnostic indicators during pathology work up.

Question 5

“Tumor of uncertain origin”

Answer 5

The treating oncologist/pathologist has a clinical inclination of the primary tumor type, but is seeking molecular confirmation.
OR, clinician wants to clarify if the tumor is a recurrence or a new primary.

Question 6

“Rare tumors with poorly defined treatment strategies”

Answer 6

Tumor type is known, but rare. and knowing the “nearestt molecular neighbor” of a more common tumor type may help to inform clinical decision-making.

Question 7

Which is false about cancers of unknown primary/tumors of unknown origin?

Answer 7

Finding the patient’s tumor origin cannot determine possible immunotherapy options.

Question 8

Primary tumor site unknown, lacks clear diagnostic indicators:

Answer 8

True CUP/TUO

Question 9

Clinician seeks knowledge of “nearest molecular neighbor” to inform decisions:

Answer 9

Rare tumors with poorly defined treatment strategies.

Question 10

Clinician has clinical inclination of the primary tumor, seeks to confirm:

Answer 10

Tumor of uncertain origin

Question 11

Tempus TO (tumor Origin) Algo, what does it do?

Answer 11

• utilizes data from existing Tempus/ xT orders
• specifically utilizes RNA expression data
• indicates most likely primary and potential tumor origin compared to RNA expression profiles in RNA database of 68 possible cancer types.
• results reviewed by Tempus pathologist with possible additional interpretive analysis as needed.

Question 12

TO is not avaialble as a stand alone option BUT-

Answer 12

it is available as an “add-on” only through xT

Question 13

It can be added on to:

Answer 13

• xT tumor+normal match OR
• xT solid tumor only
• NO additonal tissue is required

Question 14

TO requirements :

Answer 14

• tumor purity must be greater than or equal to 20%

- RNA sequencing must be completed and RNA expression must pass QC

Question 15

Section 1

Answer 15

predicted diagnosis (all those with probabilities > 35%

Question 16

Section 2

Answer 16

lower probibility diagnostic predictions (all those with probabilities between 11% and 35% )

Question 17

Section 3

Answer 17

cannot exclude (all those between 3% and 11%) only includes diagnosis names, not probibilities.

Question 18

4:

Answer 18

lists in alphabetical order all remaining tumor diagnoses with <3% predicted probability.

Question 19

Does Tempus analyze the most tumor and subtypes?

Answer 19

Yes, 68 of them.

Question 20

Why does this matter to clinicians?

Answer 20

1. identifying the primary cancer/tumor origin of a CUP/TUO has significant implications for medical management.
2. Clinicians with TUO patients are likely going to want to perform this identification to learn about options for those patients.
3. In adding TO to xT for a TUO patient, a clinician has the potential to recieve as much pertinent info as possible.
4. It’s competitive and includes more cancer sub-types .

Question 21

Key takeaways:

Answer 21

1. identification of the primary/tumor origin in a patient has significant implications for medical mgmt of a patient.
2. The Tempus TO assay utilizees RNA expression dtat to indicate the most likely cancer diagnosis from 68 possible subtypes.

Question 22

T or F, Foundation and Caris are Tempus’s two main competitiors in the tumor origin space.

Answer 22

False